New Partnership Introduces Advanced Drug Residue Testing Technology to Canadian Market

The strategic collaboration between Taizhou Kaimi Biotech and Scenesafe Trauma Scene Remediation introduces the Unow™ Drug Residue Test Device to the Canadian market, representing a significant advancement in portable detection technology for hazardous substances. This partnership combines Taizhou Kaimi Biotech's expertise in biotech innovation with Scenesafe's comprehensive understanding of Canadian safety protocols to address critical public safety concerns related to drug contamination.

The Unow™ device offers laboratory-grade identification capabilities in a portable format, enabling swift detection of trace amounts of dangerous substances including opioids, fentanyl, and methamphetamine. This technology serves multiple critical sectors, providing law enforcement agencies with rapid on-site testing capabilities during investigations, helping healthcare facilities maintain sterile environments, assisting remediation teams in validating decontamination efforts, and protecting residential and commercial properties from contamination risks.

Otis Zhao, President and Founder of Taizhou Kaimi Biotech, emphasized the technology's potential to protect communities, noting that the partnership with Scenesafe ensures the solution meets specific Canadian market requirements. Hang Ai, Founder of Scenesafe, highlighted the device's significance in addressing drug contamination risks for first responders, families, and businesses across the country. The collaboration aims to establish new standards in drug residue detection and remediation practices throughout Canada.

The Unow™ Drug Residue Test Device is scheduled for availability to Canadian clients in the second quarter of 2025, with pre-orders expected to open in the coming months. This technology represents a substantial improvement in public safety infrastructure, providing reliable detection capabilities that can prevent exposure to hazardous substances in various environments. The partnership between these two companies demonstrates how specialized expertise in biotechnology and safety protocols can combine to create innovative solutions for complex public health challenges.

This advancement in portable diagnostic technology comes at a critical time when communities across Canada face increasing challenges related to drug contamination and substance abuse. The ability to quickly and accurately identify trace amounts of dangerous substances enables more effective response strategies and better protection for vulnerable populations. The technology's deployment across multiple sectors ensures comprehensive coverage, from crime scene investigation to healthcare facility maintenance and property remediation services.